Search Result
Results for "
Alpha-Glucosidase+Inhibitors
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0089
-
Acarbose
Maximum Cited Publications
10 Publications Verification
BAY g 5421
|
Glycosidase
|
Infection
Metabolic Disease
Cancer
|
|
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
-
- HY-14860
-
|
Duvoglustat
|
Glycosidase
PI3K
|
Metabolic Disease
|
|
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
-
- HY-14860A
-
|
Duvoglustat hydrochloride
|
Glycosidase
PI3K
Bacterial
Antibiotic
|
Infection
Metabolic Disease
|
|
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
-
- HY-N7096
-
|
CTZ sodium
|
Bacterial
Antibiotic
|
Infection
|
|
Ceftezole sodium (CTZ sodium) is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria. Ceftezole sodium (CTZ sodium) is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity .
|
-
-
- HY-125713
-
|
|
Glycosidase
Enterovirus
|
Infection
|
|
Ganoderic acid Y is a α-glucosidase inhibitor with an IC50 of 170 μM for yeast α-glucosidase. Ganoderic acid Y inhibits enterovirus 71 (EV71) replication through blocking EV71 uncoating .
|
-
-
- HY-78000
-
|
4-Carbomethoxybenzaldehyde; 4-Carboxybenzaldehyde methyl ester; Terephthalaldehydic acid methyl ester; Methyl 4-formylbenzoate
|
Drug Intermediate
|
Metabolic Disease
|
|
Methyl 4-formylbenzoate (4-Carbomethoxybenzaldehyde; 4-Carboxybenzaldehyde methyl ester; Terephthalaldehydic acid methyl ester; Methyl 4-formylbenzoate) is a intermediate that can be used for the synthesis of chalcone amide α-glucosidase inhibitors .
|
-
-
- HY-N7377
-
|
|
Glycosidase
|
Metabolic Disease
|
|
Butyl isobutyl phthalate is isolated from the rhizoid of Laminaria japonica. Butyl isobutyl phthalate is a non-competitive α-glucosidase inhibitor with an IC50 value of 38 μM. Butyl isobutyl phthalate shows a hypoglycemic effect and has the potential for diabetes treatment .
|
-
-
- HY-B0089R
-
|
BAY g 5421 (Standard)
|
Reference Standards
Glycosidase
|
Metabolic Disease
Cancer
|
|
Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
-
- HY-N8517
-
|
|
Glycosidase
Apoptosis
|
Infection
Metabolic Disease
Cancer
|
|
Malabaricone B, a naturally occurring plant phenolic, is an orally active α-glucosidase inhibitor with an IC50 of 63.7 µM. Malabaricone B has anticancer, antimicrobial, anti-oxidation and antidiabetic activities .
|
-
-
- HY-131114
-
|
|
Glycosidase
|
Infection
|
|
Valiolamine, an aminocyclitol, is an alpha-glucosidase inhibitor. Valiolamine has potent alpha-glucosidase inhibitory activity against porcine intestinal sucrase, maltase and isomaltase. Valiolamine binds to porcine intestinal maltase and sucrase with Ki values of 350 nM and 30 nM, respectively .
|
-
-
- HY-N16575
-
|
|
Glycosidase
|
Metabolic Disease
|
|
16-Oxoserratenediol (Compound 11) is a serratene-type triterpenoid found in Lycopodium cernuum L.. 16-Oxoserratenediol is a α-glucosidase inhibitor with inhibition rate of 43.93% at 100 μM. 16-Oxoserratenediol can be used for the research of diabetes .
|
-
-
- HY-129131
-
|
|
Glycosidase
|
Metabolic Disease
|
|
Chrysin 6-C-arabinoside 8-C-glucoside is a α±-glucosidase inhibitors which are widely used in the study for type 2 diabetes .
|
-
-
- HY-N1218
-
|
|
Glycosidase
Bcl-2 Family
|
Others
|
|
Stellasterol is a natural product. Stellasterol has high affinity towards Bcl-2 protein (Ki: 118.05 nM). Stellasterol is a weak α-glucosidase inhibitor .
|
-
-
- HY-N2223
-
|
Ganodermadiol
|
Glycosidase
|
Metabolic Disease
|
|
Ganoderol B is a potent α-glucosidase inhibitor. Ganoderol B has high α-glucosidase inhibition with an IC50 of 48.5 μg/mL (119.8 μM) .
|
-
-
- HY-146128
-
|
|
Glycosidase
|
Metabolic Disease
|
|
Anti-hyperglycemic agent-1 (compound 10) is a potent α-Glucosidase inhibitor, with an IC50 of 0.53 μM. Anti-hyperglycemic agent-1 can be used for diabetes research .
|
-
-
- HY-152158
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-22 (Compound 7i) is a α-glucosidase inhibitor with an IC50 value of 0.64 μM. α-Glucosidase-IN-22 can be used for the research of type 2 diabetes .
|
-
-
- HY-101399R
-
|
H-γ-Glu-Phe-OH (Standard); γ-Glutamylphenylalanine (Standard)
|
Reference Standards
Endogenous Metabolite
|
Others
|
|
Ceftezole (sodium) (Standard) is the analytical standard of Ceftezole (sodium). This product is intended for research and analytical applications. Ceftezole sodium (CTZ sodium) is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria. Ceftezole sodium (CTZ sodium) is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity .
|
-
-
- HY-U00090
-
|
MOR 14; N-Methyl-1-deoxynojirimycin; N-Methylmoranolin
|
Glycosidase
|
Metabolic Disease
|
|
N-Methylmoranoline (MOR 14) is an α-glucosidase inhibitor.
|
-
-
- HY-N10426
-
|
|
Glycosidase
|
Metabolic Disease
|
|
(+)-Cembrene A (Compound 5) is a α-glucosidase inhibitor with an IC50 of 30.31 μM. (+)-Cembrene A is nontoxic towards human normal hepatocyte (LO2) cells .
|
-
-
- HY-121991
-
|
|
Glycosidase
|
Others
|
|
N-5-Carboxypentyl-1-deoxynojirimycin is an alpha-glucosidase inhibitor, and also can be used to prepare affinity matrices for binding to resins.
|
-
-
- HY-146305
-
-
-
- HY-N7095
-
|
CTZ
|
Bacterial
Antibiotic
|
Infection
|
|
Ceftezole (CTZ) is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria. Ceftezole (CTZ) is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity .
|
-
-
- HY-N7763
-
|
|
Glycosidase
|
Neurological Disease
|
|
Casuarictin is a potent and competitive α-glucosidase inhibitor with an IC50 of 0.21 μg/mL. Casuarictin is a presenilin stabilization factor like protein (PSFL) protein inhibitor. Casuarictin can be used for Alzheimer's disease research .
|
-
-
- HY-N8120
-
-
-
- HY-119593
-
-
-
- HY-N1901
-
-
-
- HY-U00266
-
-
-
- HY-N12790
-
|
Ananonin B
|
Glycosidase
|
Metabolic Disease
|
|
Arisanschinin D (Ananonin B) is an α-Glucosidase inhibitor and can be isolated from Schisandra arisanensis Hay .
|
-
-
- HY-146156
-
-
-
- HY-150960
-
-
-
- HY-134960
-
-
-
- HY-150959
-
-
-
- HY-150961
-
-
-
- HY-N9478
-
|
|
Glycosidase
|
Others
|
|
Sumaresinolic acid (compound 6) is a natural product which can be extracted from heterophyllum root . Sumaresinolic acid is a alpha-glucosidase inhibitor .
|
-
-
- HY-147879
-
-
-
- HY-172758
-
|
|
Glycosidase
|
Others
|
α-Glucosidase-IN-89 (8g) is α-glucosidase inhibitor, with an IC50 of 0.5 μM and a Ki of 0.46 µM .
|
-
-
- HY-138992
-
|
|
Glycosidase
Endogenous Metabolite
|
Others
|
|
2,3-Indolobetulin is a pentacyclic triterpene and a derivative of betulin. 2,3-Indolobetulin can be used in the synthesis of α-glucosidase inhibitors .
|
-
-
- HY-162637
-
|
|
Glycosidase
|
Metabolic Disease
|
|
CTL26 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 2.81 µM. CTL26 shows anti-diabetic efficacy .
|
-
-
- HY-131504A
-
|
|
Glycosidase
|
Metabolic Disease
|
|
Valienamine is the alpha-glucosidase inhibitor. Valienamine is the key functional component of many natural glycosidase inhibitors including the crop protectant validamycin A and the antidiabetic agent acarbose .
|
-
-
- HY-N12500
-
|
|
Glycosidase
|
Others
|
|
1'-O-Methyl neochebulinate, hydrolyzable tannin, is an α-glucosidase inhibitor with IC50 value of 59.5 μM, isolated from the fruits of Terminalia chebula Retz .
|
-
-
- HY-N4069
-
-
-
- HY-N11512
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-24 (Compound 13) is an α-Glucosidase inhibitor with an IC50 of 451 μM. α-Glucosidase-IN-24 can be isolated from Swertia kouitchensis .
|
-
-
- HY-149533
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-34 (compound 7f) is a potent α-glucosidase inhibitor (IC50: 2.90 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
|
-
-
- HY-169255
-
-
-
- HY-115978
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-2 (compound 5d) is a potent α-Glucosidase inhibitor with an IC50 of 9.48 µM. α-Glucosidase-IN-2 is an antidiabetic agent .
|
-
-
- HY-149532
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-33 (compound 7c) is a potent α-glucosidase inhibitor (IC50: 2.39 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
|
-
-
- HY-147823
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-6 (compound 18) is a competitive α-glucosidase inhibitor with an IC50 of 5.69 µM. α-Glucosidase-IN-6 has anti-diabetic potential .
|
-
-
- HY-170866
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-81 (Compound 5) is a potent α-Glucosidase inhibitor with an IC50 value of 5.30 μM. α-Glucosidase-IN-81 is promising for research of diabetes .
|
-
-
- HY-157488
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-46 is a potent α-glucosidase inhibitor with an IC50 of 26.0 μM. α-Glucosidase-IN-46 can be used for the research of type 2 diabetes .
|
-
-
- HY-N9075
-
|
|
Glycosidase
|
Cancer
|
|
9-(4′-Hydroxyphenyl)-2-methoxyphenalen-1-one is a phytoalexin and mixed competitive α-glucosidase inhibitor of Bacillus stearothermophilus (IC50: 3.86 mg/L) .
|
-
- HY-161318
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-52 (Compound 3h) is an α-glucosidase inhibitor with an IC50 of 2.8 μM. α-Glucosidase-IN-52 can be used for diabetes research .
|
-
- HY-147718
-
|
|
Glutaminase
|
Metabolic Disease
|
|
α-Glucosidase-IN-5 (compound 8) is a potent α-glucosidase inhibitor with an IC50 of 57.9 µM. α-Glucosidase-IN-5 has the potential for the research of diabetes mellitus .
|
-
- HY-151142
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-18 (7B) is an orally active α-glucosidase inhibitor with an IC50 value of 3.96 μM. α-Glucosidase-IN-18 has antidiabetic activity .
|
-
- HY-B0089A
-
|
Bay-g 5421 sulfate
|
Glycosidase
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-151141
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-17 (Compound 12B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.79 μM. α-Glucosidase-IN-17 shows antidiabetic activity .
|
-
- HY-147964
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-9 (compound 7) is a potent α-glucosidase inhibitor, with an IC50 of 55.6 μM. α-Glucosidase-IN-9 can be used for type II diabetes research .
|
-
- HY-151135
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-15 (Compound 14B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.34 μM. α-Glucosidase-IN-15 shows antidiabetic activity .
|
-
- HY-147965
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-10 (compound 13) is a potent α-glucosidase inhibitor, with an IC50 of 92.7 μM. α-Glucosidase-IN-10 can be used for type II diabetes research .
|
-
- HY-170606
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-79 (Compound 4d9) is a non-competitive α-Glucosidase inhibitor with an IC50 of 2.11 μM, which is more potent than existing α-Glucosidase inhibitors such as Acarbose (HY-B0089) (IC50 of 327.0 μM) and HXH8r (IC50 of 15.32 μM). α-Glucosidase-IN-79 is non-cytotoxic to human normal hepatocyte (LO2) cells and shows good metabolic stability in rat plasma. α-Glucosidase-IN-79 holds promise for research into type 2 diabetes .
|
-
- HY-151143
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-19 (Compound 6B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.63 μM. α-Glucosidase-IN-19 shows anti-diabetic activity .
|
-
- HY-N12664
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-54 (compound 2) is a α-glucosidase inhibitor with the IC50 of 0.011 mM, and can be isolated form Syzygium jambos (L.). α-Glucosidase-IN-54 can be used for study of diabetes .
|
-
- HY-158697
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-65 (compound 5) is a Schiff base derivative of 3,4-dihydroxyphenylacetic acid. α-Glucosidase-IN-65 is a potent α-glucosidase inhibitor, with an IC50 of 12.84 μM .
|
-
- HY-151145
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 2.62 μM. α-Glucosidase-IN-21 shows anti-diabetic activity .
|
-
- HY-151144
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-20 (Compound 3B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.01 μM. α-Glucosidase-IN-20 shows anti-diabetic activity .
|
-
- HY-N12689
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-56 (compound 1) is an orally active, potent α‐glucosidase inhibitor with an IC50 value of 45.86 μM. α-Glucosidase-IN-56 has potent anti-glycation activities .
|
-
- HY-N13188
-
|
Michelioside A
|
Glycosidase
|
Cancer
|
|
2'-Rhamnoechinacoside (Michelioside A), a compound of phenylethanoid glycosides, is a α-glucosidase inhibitor with anti-tumor activity, which is derived from Phlomis stewartii. 2'-Rhamnoechinacoside can be used for research of UV-absorbing and cancers .
|
-
- HY-155344
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-38 (Compound 11j) is a potent inhibitor of α-glucosidase inhibitor with IC50 of 12.44±0.38 μM.α-Glucosidase-IN-38 plays an important role in Diabetes mellitus (DM) .
|
-
- HY-162697
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-69 (compound 5k) is a competitive α-glucosidase inhibitor with an IC50 of 26.8 µM and a Ki value of 26.0 µM. α-Glucosidase-IN-69 has the potential for the diabetes research .
|
-
- HY-162541
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-64 (compound 10) is a potent α-glucosidase inhibitor with an IC50 value of 8.62 µM. α-Glucosidase-IN-64 is a polycyclic polyprenylated acylphloroglucinol that can be isolated from hypericum beanii .
|
-
- HY-154998
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-27 (compound 8l) is an α-glucosidase inhibitor (IC50=25.78 μM). α-Glucosidase-IN-27 has the potential to study type 2 diabetes (D2M) .
|
-
- HY-N12006
-
|
|
Glycosidase
|
Others
|
|
6,8-Dihydroxy-1,2,7-trimethoxy-3-methylanthraquinone (compound 1) is an anthraquinone α-glucosidase inhibitor (IC50:185 μM), which can be isolated from Cassia seeds .
|
-
- HY-163907
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-71 (Compound 7h) is a competitive α-glucosidase inhibitor (IC50: 98.0 µM). α-Glucosidase-IN-71 can be used for research of carbohydrate-related diseases, especially type 2 diabetes mellitus .
|
-
- HY-149332
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-26 (Compound 7i) is an α-glucosidase inhibitor (IC50=4.63 µM). α-Glucosidase-IN-26 can be used in the study of type 2 diabetes mellitus (T2DM) .
|
-
- HY-172138
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-84 (Compound 7j) is a competitive α-glucosidase inhibitor with an IC50 of 50 μM and a Ki of 32 μM. α-Glucosidase-IN-84 holds potential for use in the field of metabolic diseases, such as the study of type 2 diabetes .
|
-
- HY-149409
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-31 (compound R1) is an orally active, potent α-Glucosidase inhibitor with an IC50 value of 10.1 μM. α-Glucosidase-IN-31 significantly reduces the blood glucose level and has antidiabetic activity .
|
-
- HY-149342
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-29 (compound 19) is a α-glucosidases inhibitor (IC50=1.21 μM, Ki=1.80 μM). α-Glucosidase-IN-29 ca be used for research of diabetes and related diseases .
|
-
- HY-173183
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-87 (Compound 11c) is an orally active α-glucosidase inhibitor with an IC50 value of 119.7 μM. α-Glucosidase-IN-87 has hypoglycemic activity and can be used in the research of metabolic diseases such as diabetes .
|
-
- HY-161421
-
|
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-61 (Compd 1j), a competitive α-glucosidase inhibitor, demonstrates excellent inhibition with an IC50 of 0.73 μM. α-Glucosidase-IN-61 (Compd 1j) is used for the research of type 2 diabetes mellitus .
|
-
- HY-N13173
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-70 (compound 9) is an α-glucosidase inhibitor (IC50=31.1 μM) isolated from the traditional Chinese herbal medicine Swertia mussotii. α-Glucosidase-IN-70 can be used in the research of diabetes .
|
-
- HY-162893
-
|
|
Glycosidase
|
Metabolic Disease
|
|
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC50 value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .
|
-
- HY-163975
-
|
|
Glycosidase
|
Cancer
|
|
α-Glucosidase-IN-72 (compound 5i) is a 2,4-dichloro-N-phenylacetamide derivative and an α-glucosidase inhibitor (IC50: 6 μM). α-Glucosidase-IN-72 does not follow Lipinski's "rule of five" and does not induce cancer .
|
-
- HY-121323R
-
|
|
Reference Standards
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-N7096R
-
|
CTZ sodium (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Ceftezole (sodium) (Standard) is the analytical standard of Ceftezole (sodium). This product is intended for research and analytical applications. Ceftezole sodium (CTZ sodium) is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria. Ceftezole sodium (CTZ sodium) is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity .
|
-
- HY-N15138
-
|
|
Glycosidase
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Sativanone is a compound that can be isolated from Dalbergia tonkinensis. Sativanone is a potent α-glucosidase inhibitor, with an EC50 of 0.357 mg/mL for rat α-glucosidase. Sativanone has antibacterial activity against Ralstonia solanacearum. Sativanone also has anti-senescent and antioxidant effects .
|
-
- HY-N18381
-
|
|
Glycosidase
|
Others
|
|
Deacylhericene is an α-glucosidase inhibitor with an IC50 of 12.5 μM. Deacylhericene functionally inhibits the activity of α-glucosidase .
|
-
- HY-118434
-
|
|
Glycosidase
|
Metabolic Disease
|
|
3,4-Methylenedioxychalcone (Compound 40) is an α-glucosidase inhibitor with an IC50 of 1870 μM. 3,4-Methylenedioxychalcone is applicable to the research of type 2 diabetes .
|
-
- HY-179092
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-100 (compound 6) is a potent alpha glucosidase inhibitor. α-Glucosidase-IN-100 can be used to study metabolic diseases such as diabetes .
|
-
- HY-N17553
-
|
|
Glycosidase
|
Metabolic Disease
|
|
N-Formyldehydroanonaine is a potent α-glucosidase inhibitor with an IC50 of 104.6 μM against yeast α-glucosidase. N-Formyldehydroanonaine can be used for the research of diabetes mellitus .
|
-
- HY-N17925
-
|
|
Glycosidase
|
Metabolic Disease
|
|
Falandioside B is an α-glucosidase inhibitor with an IC50 of 107.52 μM. Falandioside B scavenges ABTS radical cations. Falandioside B is applicable to research related to postprandial hyperglycemia .
|
-
- HY-W354556
-
|
|
Glycosidase
|
Inflammation/Immunology
|
|
3-Hydroxyproline is a non-glycosyl microbial α-glucosidase inhibitor. 3-Hydroxyproline is used in the research of diabetes (type 2 diabetes/non-insulin-dependent diabetes mellitus) .
|
-
- HY-178742
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-99 (Compound 21) is an α-Glucosidase inhibitor, with an IC50 of 52.79 μM. α-Glucosidase-IN-99 can be used for the study of type 2 diabetes .
|
-
- HY-174839
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-93 (Compound 5b) is a potent α-glucosidase inhibitor with an IC50 value of 49.18 nM. α-Glucosidase-IN-93 is promising for research of type 2 diabetes .
|
-
- HY-174840
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-94 (Compound 6e) is a potent α-glucosidase inhibitor with an IC50 value of 0.1412 mM. α-Glucosidase-IN-94 is promising for research of type 2 diabetes .
|
-
- HY-169251
-
-
- HY-182776
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-115 (compound 3m) is a non-competitive α-Glucosidase inhibitor with an IC50 value of 45.07 μM. α-Glucosidase-IN-115 is applicable to the research of type 2 diabetes .
|
-
- HY-175494
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-96 (Compounds 7b) is a potent α-Glucosidase inhibitor with IC50 values of 9.23 ~ 9.61 μM. α-Glucosidase-IN-96 can be used in diabetes research .
|
-
- HY-105528
-
|
|
Glycosidase
|
Metabolic Disease
|
|
MDL-25637 is an α-glucosidase inhibitor. MDL-25637 can inhibit the activity of sucrose enzyme, maltase, isomaltase, glucose amylase, and trehalose in the intestinal tract of rats. MDL-25637 can be used in the research of diabetes .
|
-
- HY-180577
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-108 (Compound 2h) is a potent competitive α-glucosidase inhibitor with an IC50 of 9.64 μM and a Ki of 7.39 μM. α-Glucosidase-IN-108 can be used for the research of type 2 diabetes .
|
-
- HY-186199
-
|
|
Glycosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
α-Glucosidase-IN-117 is a low-activity α-glucosidase (α-glucosidase) inhibitor belonging to the coumarin derivative class, with an inhibition rate of 19.51% at 100 μM. α-Glucosidase-IN-117 can be used in diabetes research .
|
-
- HY-178138
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-97 (Compound 9i) is a highly selective α-glucosidase inhibitor (IC50=1.05 μM). α-Glucosidase-IN-97 is promising for research of type 2 diabetes mellitus (T2DM) .
|
-
- HY-157489
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-47 (compound 8H) is a non-competitive α-glucosidase (α-glucosidase) inhibitor with IC50 value is 38.2 μM and Ki value is 38.2 μM. α-Glucosidase-IN-47 can be used in diabetes research. .
|
-
- HY-179508
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-103 (compound 5u) is a potent and competitive α-Glucosidase inhibitor with an IC50 of 5.38 µM and a Ki of 3.57 µM. α-Glucosidase-IN-103 can be used for type 2 diabetes (T2DM) research .
|
-
- HY-169117
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-74 (Compound 7d), an isatin-thiazole derivative, is a α-glucosidase inhibitor. α-Glucosidase-IN-74 exhibits antidiabetic activity by decreasing glycaemia and triglyceride levels in Streptozotocin (HY-13753)-induced diabetic animals .
|
-
- HY-148575
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-23 is an orally active α-Glucosidase inhibitor. α-Glucosidase-IN-23 decreases blood glucose by a-glucosidase inhibition with an IC50 value of 4.48 μM. α-Glucosidase-IN-23 can be used for the research of diabetes .
|
-
- HY-78000R
-
|
4-Carbomethoxybenzaldehyde (Standard); 4-Carboxybenzaldehyde methyl ester (Standard); Terephthalaldehydic acid methyl ester (Standard); Methyl 4-formylbenzoate (Standard)
|
Reference Standards
Drug Intermediate
|
Metabolic Disease
|
|
Methyl 4-formylbenzoate (4-Carbomethoxybenzaldehyde) (Standard) is the analytical standard of Methyl 4-formylbenzoate (HY-78000). This product is intended for research and analytical applications. Methyl 4-formylbenzoate is a drug intermediate that can be used to synthesis chalcone amide α-glucosidase inhibitors .
|
-
- HY-151138
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin (HY-13753)-induced diabetic rats. Antidiabetic activity .
|
-
- HY-168944
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
ABCB1-IN-4 (Compound C6z) is an orally active and potent dual α-amylase and α-glucosidase inhibitor with IC50 values of 1.63 μM and 0.14 μM, respectively. ABCB1-IN-4 is promising for research of diabetes .
|
-
- HY-161999
-
|
|
Glycosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
α-Glucosidase-IN-73 (compound 16b) is an α-Glucosidase inhibitor with IC50 of 0.158 μM. α-Glucosidase-IN-73 can activate PPAR γ. α-Glucosidase-IN-73 can be used in anti-diabetic and anti-inflammatory studies .
|
-
- HY-181476
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-113 is an α-glucosidase inhibitor with an IC50 of 17.52 μM. α-Glucosidase-IN-113 shows antiglycating activity and inhibits advanced glycation end-product formation. α-Glucosidase-IN-113 can be used for the research of type 2 diabetes .
|
-
- HY-180275
-
|
|
Glycosidase
|
Inflammation/Immunology
|
|
α-Glucosidase-IN-107 (Compound 1) is an α-glucosidase inhibitor with an IC50 of 1.01 μM. α-Glucosidase-IN-107 binds to the allosteric site of α-glucosidase. α-Glucosidase-IN-107 shows non-cytotoxic to normal lung fibrolast cells .
|
-
- HY-179141
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-23 (Compound 5e) is a α-Amylase/α-Glucosidase inhibitor with IC50 values of 73.68 nM for α-glucosidase and 146.18 nM for α-amylase. α-Amylase/α-Glucosidase-IN-23 can be used in the research of hypoglycemia .
|
-
- HY-126535
-
|
|
Glycosidase
|
Metabolic Disease
Cancer
|
|
Magnoloside B is an α-glucosidase inhibitor (IC50=0.69 mM), which can be obtained from Magnolia officinalis stem bark. Magnoloside B shows moderate inhibitory activity against MGC-803 and HepG2 cells. Magnoloside B has the potential to study cancer and diabetes .
|
-
- HY-B0089S
-
|
BAY g 5421-d4
|
Isotope-Labeled Compounds
Glycosidase
|
Metabolic Disease
Cancer
|
|
Acarbose-d4 (BAY g 5421-d4) is deuterium labeled Acarbose. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-149668
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-41 (compound 5o) is a potent α-glucosidase inhibitor. α-Glucosidase-IN-41 can arise the changed secondary structure of α-Glu to hinder enzyme catalytic activity. α-Glucosidase-IN-41 can be used for diabetes mellitus research .
|
-
- HY-161764
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-67 (compound 5k) is a potent α-Glucosidase inhibitor with IC50 values of 0.31, 4.51 µM for alpha-glucosidase and alpha-amylase, respectively. α-Glucosidase-IN-67 has the potential for the research of type-2 diabetes .
|
-
- HY-150560
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-11 is a highly permeable competitive α-glucosidase inhibitor with the IC50 value of 0.56 μM. α-Glucosidase-IN-11 binds to Trp residues in α-glucosidase and regulates protein folding. α-Glucosidase-IN-11 can be used to regulate blood glucose levels .
|
-
- HY-159796A
-
|
GR69153
|
Bacterial
Antibiotic
Glycosidase
|
Infection
Metabolic Disease
|
|
Ceftezole (GR69153) is a broad-spectrum cephalosporin antibiotic and an α-glucosidase inhibitor. Ceftezole inhibits bacterial cell lysis by inhibiting cell wall synthesis and binding to penicillin-binding proteins (PBPs). Ceftezole exhibits in vivo anti-diabetic activity in diabetic mice. Ceftezole can be used in antibacterial and anti-diabetic research .
|
-
- HY-N12761
-
|
|
Phosphatase
Glycosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
Penpaxilloids A (Compound 1) is a non-competitive inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 value of 8.60 μM. Penpaxilloids A can be isolated from the fungus Penicillium sp. ZYX-Z-143. Penpaxilloids A is also an α-glucosidase (α-glucosidase) inhibitor with anti-inflammatory activity .
|
-
- HY-B0025
-
|
|
Glycosidase
|
Metabolic Disease
|
|
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis .
|
-
- HY-163433
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-57 (Compound 10c) is a competitive and orally active α-glucosidase inhibitor with an IC50 value of 0.180 μM and a Ki of 0.15 μM. α-Glucosidase-IN-57 can reduce fasting and overall blood glucose levels in mice, and can be used for anti-diabetes research .
|
-
- HY-N10440
-
|
|
Glycosidase
|
Infection
Inflammation/Immunology
|
|
3-Oxo-hop-22(29)-ene is a yeast α-glucosidase inhibitor. 3-Oxo-hop-22(29)-ene shows a moderate effect on the viability of T. cruzi and L. mexicana. 3-Oxo-hop-22(29)-ene shows marginal activity of anti-inflammatory .
|
-
- HY-175170
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-95 (Compound 21c) is a competitive α-Glucosidase inhibitor with an IC50 of 0.44 μM. α-Glucosidase-IN-95 has a significant inhibitory potency without cytotoxicity to normal cells. α-Glucosidase-IN-95 can be used for metabolic disorders like diabetes mellitus research .
|
-
- HY-131114R
-
|
|
Glycosidase
Reference Standards
|
Infection
|
|
Valiolamine (Standard) is the analytical standard of Valiolamine (HY-13114). This product is intended for research and analytical applications. Valiolamine, an aminocyclitol, is an alpha-glucosidase inhibitor. Valiolamine has potent alpha-glucosidase inhibitory activity against porcine intestinal sucrase, maltase and isomaltase. Valiolamine binds to porcine intestinal maltase and sucrase with Ki values of 350 nM and 30 nM, respectively .
|
-
- HY-158037
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-55 (Compound 8g) is an orally active and competitive alpha-glucosidase inhibitor, with IC50 and Ki values of 12.1 and 9.66 µM, respectively. α-Glucosidase-IN-55 can be used for the research into type 2 diabetes mellitus (T2DM) to improve blood sugar control and metabolic health .
|
-
- HY-179154
-
|
|
Glycosidase
Cytochrome P450
|
Metabolic Disease
|
|
α-Glucosidase-IN-101 (Compound 13j) is an uncompetitive α-glucosidase inhibitor, with an IC50 of 120 nM. α-Glucosidase-IN-101 properly inhibits CYP1A2, CYP2C19, and CYP2C9 isoforms of cytochrome P450. α-Glucosidase-IN-101 can be used in the research of diabetes .
|
-
- HY-N7170
-
|
|
Glycosidase
|
Metabolic Disease
|
|
(-)-6β-Hydroxy-5β,8β,9β,10α-cleroda-3,13-dien-16,15-olid-18-oic acid (compound 4) is a α-Glucosidase inhibitor with an IC50 value of 577.7 µM .
|
-
- HY-N13813
-
|
|
Phosphatase
Glycosidase
|
Others
|
|
Ethyl-3,5-di-O-caffeoylquinate is an ethyl caffeoylquinate (ECQ), and ECQ analogs are potential α-glucosidase (α-glucosidase) inhibitors and PTP1B inhibitors. Ethyl-3,5-di-O-caffeoylquinate, which can be isolated from the flower buds of Lonicera macranthoides, is an isomer of chlorogenic acid (ethyl dicaffeoylquinate) .
|
-
- HY-182289
-
|
|
Glycosidase
|
Metabolic Disease
|
|
LY-23 is an orally active α-glucosidase inhibitor (Ki = 0.05 μM), with IC50 values of 0.18 μM, 0.14 μM and 0.51 μM against maltase, sucrase and isomaltase, respectively. LY-23 reduces the level of postprandial blood glucose elevation. LY-23 is applicable to research related to postprandial hyperglycemia .
|
-
- HY-14860R
-
|
Duvoglustat (Standard)
|
Reference Standards
Glycosidase
PI3K
|
Metabolic Disease
|
|
1-Deoxynojirimycin (Standard) is the analytical standard of 1-Deoxynojirimycin. This product is intended for research and analytical applications. 1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
- HY-174223
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-90 (Compound 7b) is an α-Glucosidase inhibitor (IC50: 14.48 nM). α-Glucosidase-IN-90 binds to HIS:280 and ASN:415 residues of α-glucosidase via hydrogen bonds, inhibiting the activity of the enzyme. α-Glucosidase-IN-90 can be used in the study of diabetes .
|
-
- HY-147711
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent α-amylase/α-glucosidase inhibitor with IC50s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .
|
-
- HY-W009417
-
|
|
Environmental Pollutants
Glycosidase
|
Metabolic Disease
|
|
Cedryl acetate is an orally active α-glucosidase inhibitor with an IC50 of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .
|
-
- HY-N15602
-
|
|
Glycosidase
NO Synthase
|
Inflammation/Immunology
|
|
Isosojagol (Compound 5) is a α-Glucosidase inhibitor with an IC50 of 32.2 μM. Isosojagol can be isolated from the Roots of Dolichos trilobus. Isosojagol has anti-inflammatory activity and inhibits LPS (HY-D1056A1)-induced NO production in RAW264.7 cells. Isosojagol can be used for fracture, soft tissue injuries and rheumatoid arthritis research .
|
-
- HY-105291
-
|
|
Glycosidase
Bacterial
|
Infection
Metabolic Disease
|
|
CKD-711 is an orally active aminooligosaccharide α-glucosidase inhibitor with an IC50 of 78 μg/mL. CKD-711 also inhibits porcine intestinal maltase and sucrose with IC50 values of 2.5 and 0.5 μg/mL. CKD-711 shows selective antibacterial activity against Comamonas terrigena. CKD-711 can be used for the researches of infection and metabolic disease, such as diabetes .
|
-
- HY-181091
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-109 is an orally active α-glucosidase inhibitor with an IC50 of 0.0136 μM. α-Glucosidase-IN-109 modulates carbohydrate and lipid metabolism, reduces fasting blood glucose levels, alleviates weight loss, and exhibits protective effects on liver and kidney function. α-Glucosidase-IN-109 can be used in research related to type 2 diabetes .
|
-
- HY-149341
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-28 (Compound 18) is a α-Glucosidase inhibitor (IC50: 0.62 μM, Ki: 3.93 μM). α-Glucosidase-IN-28 binds to α-glucosidase at the original binding site (OBS), and forms multiple hydrophobic interactions with nearby amino acids. α-Glucosidase-IN-28 can be used for research of diabetes and related diseases .
|
-
- HY-B0025R
-
|
|
Reference Standards
Glycosidase
|
Metabolic Disease
|
|
Voglibose (Standard) is the analytical standard of Voglibose. This product is intended for research and analytical applications. Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis[1].
|
-
- HY-181253
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-111 (Compound 5d) is an α-glucosidase (α-Glucosidase) inhibitor with a IC50 of 34.99 μg/mL. α-Glucosidase-IN-111 effectively scavenges DPPH free radicals and ABTS free radicals, with IC50 values of 5.33 and 5.84 μg/mL, respectively. α-Glucosidase-IN-111 can be used in the research of type 2 diabetes .
|
-
- HY-N6675
-
|
|
Amylases
Glycosidase
|
Inflammation/Immunology
|
|
Gardenia yellow is a competitive inhibitor of α-Amylase (HY-B2193) and α-glucosidase. Gardenia yellow can bind to the catalytic sites of α-Amylase and α-glucosidase, inhibit starch digestion, and significantly increase the contents of resistant starch and slowly digestible starch in starch-based systems. Gardenia yellow reduces the glycemic index and hydrolysis index. Gardenia yellow can be used in diabetes-related research .
|
-
- HY-163005
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC50: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .
|
-
- HY-W749516
-
|
|
Isotope-Labeled Compounds
Glycosidase
|
Metabolic Disease
|
|
Voglibose- 13C3 is the 13C-labeled Voglibose (HY-B0025). Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis.
|
-
- HY-N11728
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
2,7"-Phloroglucinol-6,6'-bieckol is an orally active dual α-amylase/α-glucosidase inhibitor with IC50 values of 6.94 μM and 23.35 μM respectively. 2,7"-Phloroglucinol-6, 6'-bieckol alleviates postprandial hyperglycemia in diabetic mice. 2,7"-Phloroglucinol-6,6'-bieckol can be used in diabetes research .
|
-
- HY-182460
-
|
|
Glycosidase
|
Metabolic Disease
Cancer
|
|
Gambogin is an α-glucosidase inhibitor, found in the resin and dry latex of Garcinia hanburyi. Gambogin exists as an inseparable diastereomeric pair of C-2 epimers (8a and 8b), with 8a having an α-glucosidase inhibitory IC50 of 209.2 μM and 8b showing α-glucosidase inhibitory IC50 > 300 μM. Gambogin can be used for the research of type 2 diabetes and cervical cancer .
|
-
- HY-172757
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-88 (Compound 3K) is an orally active and potent α-glucosidase inhibitor with an IC50 value of 6.40 µM. α-Glucosidase-IN-88 inhibits carbohydrate hydrolysis by blocking the enzyme's ability to break down glycosidic bonds, thereby reducing postprandial blood glucose levels. α-Glucosidase-IN-88 is promising for research of type 2 diabetes mellitus (T2DM) .
|
-
- HY-W009417R
-
|
|
Reference Standards
Glycosidase
Environmental Pollutants
|
Metabolic Disease
|
|
Cedryl acetate (Standard) is the analytical standard of Cedryl acetate. This product is intended for research and analytical applications. Cedryl acetate is an orally active α-glucosidase inhibitor with an IC50 of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .
|
-
- HY-156078
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-32 (compound f26) is a reversible, noncompetitive and orally active α-glucosidase inhibitor with an IC50 value of 3.07 μM. α-Glucosidase-IN-32 complex with α-glucosidase through hydrogen bonds and hydrophobic interactions, led to changes in the conformation and secondary strictures of α-glucosidase and further the inhibition of the enzymatic activity. α-Glucosidase-IN-32 can be used for diabetic disease research .
|
-
- HY-173130
-
|
|
Glycosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC50 of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes .
|
-
- HY-179698
-
|
|
Glycosidase
Amylases
|
Metabolic Disease
|
|
α-Glucosidase-IN-105 is a selective and potent α-Glucosidase inhibitor with an IC50 of 31.36 μM. α-Glucosidase-IN-105 also inhibits α-Amylase (IC50 = 104.2 μM). α-Glucosidase-IN-105 exhibits inhibitory effects comparable to the standard drug \rAcarbose (HY-B0089). α-Glucosidase-IN-105 can be used for the research of type 2 diabetes .
|
-
- HY-N17717
-
|
Flavosativaside
|
Glycosidase
|
Metabolic Disease
|
|
Vitexin-2''-O-glucoside (Flavosativaside) is a potent and selective alpha-glucosidase inhibitor found in hawthorn leaf flavonoids. Vitexin-2''-O-glucoside can reversibly inhibit the α-glucosidase activity on the brush border of the small intestine, and its inhibitory effect is superior to that of the Acarbose (HY-B0089). Vitexin-2''-O-glucoside can be used for the research of type 2 diabetes .
|
-
- HY-181353
-
|
|
Glycosidase
|
Metabolic Disease
Cancer
|
|
α-Glucosidase-IN-112 is an α-glucosidase inhibitor with an IC50 of 2.03 μM and a Ki of 0.44 μM. α-Glucosidase-IN-112 exerts antioxidant effects by scavenging ABTS + free radicals. α-Glucosidase-IN-112 exerts antiproliferative effects by inhibiting the proliferation of bladder cancer cells. α-Glucosidase-IN-112 can be used in research related to type 2 diabetes and bladder cancer .
|
-
- HY-N17855
-
|
|
Glycosidase
Reactive Oxygen Species (ROS)
|
Metabolic Disease
|
|
Guavinoside B is an orally active α-glucosidase inhibitor with an IC50 of 0.21 mM. Guavinoside B upregulates the expressions of Nrf2, GCLC and NQO1 induced by Acetaminophen (HY-66005), downregulates the expression of p-JNK, and reduces intracellular ROS levels. Guavinoside B decreases serum TNF-α levels induced by Acetaminophen, alleviates hepatocellular infiltration and necrosis, and improves liver-related biochemical parameters. Guavinoside B is applicable to the research of diabetes and Acetaminophen-induced liver injury .
|
-
- HY-N7683
-
|
|
Glycosidase
|
Metabolic Disease
|
|
Prunetin 5-O-β-D-glucopyranoside is an isoflavone. Prunetin 5-O-β-D-glucopyranoside can be isolated from the pedicels of Prunus avium and Prunus cerasus. Prunetin 5-O-β-D-glucopyranoside acts as a non-competitive α-glucosidase inhibitor, with a IC50 of 56.05 μg/mL and a Ki of 121 μg/mL against Saccharomyces cerevisiae α-glucosidase. Prunetin 5-O-β-D-glucopyranoside can be used in studies related to type 2 diabetes .
|
-
- HY-149579
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-36 (compound 5g) is a potent α-glucosidase inhibitor, with an IC50 of 6.69 ± 0.18 μM, Ki and Kis of 1.65 μM and 4.54 μM, respectively. α-Glucosidase-IN-36 may inhibit α-glucosidase activity by binding with its active site as well as changing the secondary structure of α-glucosidase. α-Glucosidase-IN-36 can be used for type 2 diabetes mellitus (T2DM) research .
|
-
- HY-182311
-
|
|
Aldose Reductase
Glycosidase
|
Metabolic Disease
|
|
ALR2/α-Glucosidase-IN-1 (Compound 4) is a competitive ALR2 inhibitor and competitive α-glucosidase inhibitor, with an IC50 of 0.250 μM against ALR2 and an IC50 of 0.561 μM against α-glucosidase. ALR2/α-Glucosidase-IN-1 binds to the active sites of ALR2 and α-glucosidase, and inhibits enzymatic activity by competing with their respective substrates. ALR2/α-Glucosidase-IN-1 can be used in diabetes-related research .
|
-
- HY-N2168
-
|
(+)-Pinoresinol 4-O-β-D-glucopyranoside
|
Glycosidase
Estrogen Receptor/ERR
Phosphodiesterase (PDE)
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Pinoresinol 4-O-β-D-glucopyranoside ((+)-Pinoresinol 4-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor, with an IC50 of 48.13 μg/mL. Pinoresinol 4-O-β-D-glucopyranoside binds to estrogen receptors. Pinoresinol 4-O-β-D-glucopyranoside inhibits phosphodiesterase. Pinoresinol 4-O-β-D-glucopyranoside exhibits various activities such as antioxidant, anti-inflammatory, anti-hyperglycemic, hepatoprotective and anti-epileptic effects .
|
-
- HY-162373
-
|
|
Amylases
Glycosidase
P-glycoprotein
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .
|
-
- HY-N17439
-
|
|
Glycosidase
|
Metabolic Disease
|
|
4-Ethoxy-5,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one is a naphthalene derivative and a weak α-glucosidase inhibitor. 4-Ethoxy-5,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one can be found in the leaves of Cyclocarya paliurus. 4-Ethoxy-5,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one can be used for the research of diabetes .
|
-
- HY-N0946
-
|
(-)-Pinoresinol 4-O-β-D-glucopyranoside
|
Glycosidase
|
Metabolic Disease
|
|
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
|
-
- HY-178383
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-98 is a potent orally active α-Glucosidase inhibitor with an IC50 of 18.1 μM. α-Glucosidase-IN-98 reversibly binds with α-Glucosidase via hydrogen bonds, electrostatic interactions and hydrophobic effects, which induces significant conformational alterations in the secondary structure of α-Glucosidase. α-Glucosidase-IN-98 decreases postprandial hyperglycemia in Starch (HY-B2225B)/Sucrose (HY-B1779)-challenged mice. α-Glucosidase-IN-98 can be used for type 2 diabetes mellitus (T2DM) research .
|
-
- HY-173411
-
|
|
Glycosidase
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL). DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research .
|
-
- HY-N2168R
-
|
(+)-Pinoresinol 4-O-β-D-glucopyranoside (Standard)
|
Glycosidase
Reference Standards
Estrogen Receptor/ERR
Phosphodiesterase (PDE)
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Pinoresinol 4-O-β-D-glucopyranoside (Standard) is the analytical standard of Pinoresinol 4-O-β-D-glucopyranoside (HY-N2168). This product is intended for research and analytical applications. Pinoresinol 4-O-β-D-glucopyranoside is an orally active α-glucosidase inhibitor, with an IC50 of 48.13 μg/mL. Pinoresinol 4-O-β-D-glucopyranoside binds to estrogen receptors. Pinoresinol 4-O-β-D-glucopyranoside inhibits phosphodiesterase. Pinoresinol 4-O-β-D-glucopyranoside exhibits various activities such as antioxidant, anti-inflammatory, anti-hyperglycemic, hepatoprotective and anti-epileptic effects .
|
-
- HY-N0419
-
|
Quercetin-7-O-β-D-glucopyranoside
|
Glycosidase
c-Kit
MMP
VEGFR
Aurora Kinase
|
Metabolic Disease
Cancer
|
|
Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC50 of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer .
|
-
- HY-N17771
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
(6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate is a selective α-glucosidase inhibitor (IC50=10.53 μg/mL) with anti-hepatic fibrosis and anti-diabetic properties. It also inhibits the growth of mouse hepatic stellate cells (t-HSC/Cl-6) with an IC50 of 109.2 μg/mL. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be isolated from the ester derivatives of Impatiens balsamina L. flowers. (6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate can be used in research related to hepatic fibrosis and type 2 diabetes.
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-78000
-
|
4-Carbomethoxybenzaldehyde; 4-Carboxybenzaldehyde methyl ester; Terephthalaldehydic acid methyl ester; Methyl 4-formylbenzoate
|
Biochemical Assay Reagents
|
|
Methyl 4-formylbenzoate (4-Carbomethoxybenzaldehyde; 4-Carboxybenzaldehyde methyl ester; Terephthalaldehydic acid methyl ester; Methyl 4-formylbenzoate) is a intermediate that can be used for the synthesis of chalcone amide α-glucosidase inhibitors .
|
-
- HY-78000R
-
|
4-Carbomethoxybenzaldehyde (Standard); 4-Carboxybenzaldehyde methyl ester (Standard); Terephthalaldehydic acid methyl ester (Standard); Methyl 4-formylbenzoate (Standard)
|
Biochemical Assay Reagents
|
|
Methyl 4-formylbenzoate (4-Carbomethoxybenzaldehyde) (Standard) is the analytical standard of Methyl 4-formylbenzoate (HY-78000). This product is intended for research and analytical applications. Methyl 4-formylbenzoate is a drug intermediate that can be used to synthesis chalcone amide α-glucosidase inhibitors .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-101399R
-
|
H-γ-Glu-Phe-OH (Standard); γ-Glutamylphenylalanine (Standard)
|
Reference Standards
Endogenous Metabolite
|
Others
|
|
Ceftezole (sodium) (Standard) is the analytical standard of Ceftezole (sodium). This product is intended for research and analytical applications. Ceftezole sodium (CTZ sodium) is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria. Ceftezole sodium (CTZ sodium) is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity .
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0089S
-
|
|
|
Acarbose-d4 (BAY g 5421-d4) is deuterium labeled Acarbose. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
-
- HY-W749516
-
|
|
|
Voglibose- 13C3 is the 13C-labeled Voglibose (HY-B0025). Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: